Pulmatrix, a biopharmaceutical company, filed Form S-4 related to its planned merger with Eos SENOLYTIX, a biotech focused on aging-related therapies. The merger, expected to close in Q3 2026, aims to combine Pulmatrix's inhaled drug technology with Eos's gerotherapeutic peptides targeting mitochondrial dysfunction. Pulmatrix is also seeking to out-license or monetize its clinical assets, including its iSPERSE™ technology and drug candidates PUR1900, PUR3100, and PUR1800. Financially, Pulmatrix reported reduced expenses and a cash balance of $2.2 million as of June 30, 2026, with operations funded through the merger closing. This merger could enhance the combined company's drug development pipeline and market potential.
XRP is nearing a key technical point where it needs to close above $1.53 on a four-hour chart to confirm a breakout. The token briefly hit $1.55 but failed to sustain above $1.53, leaving the breakout unconfirmed. If confirmed, the next target is $1....
Ten years ago, Intel's market value was about 28 times greater than AMD's. Today, AMD's market value has grown significantly and is now approximately 60% higher than Intel's. This dramatic shift highlights AMD's rise in the semiconductor industry and...
OPEC+ decided to keep oil production targets unchanged for November, reflecting ongoing export disruptions caused by the US-Israeli conflict with Iran. Despite rising flows through the Strait of Hormuz, Gulf producers are pumping below their quotas, ...
Tokenized stocks on the Solana blockchain have reached $12.4 billion in decentralized exchange (DEX) trading volume in 2026, with Raydium leading at $6.1 billion. Solana dominates global on-chain equity DEX trading, capturing about 95% during peak pe...
Bitcoin surged past $84,000 on October 2, marking a 43% gain in Q3 2026 and outperforming gold and many stocks. This rally is supported by a 60% increase in Bitcoin futures open interest and recent SEC proposals allowing broader crypto custody option...
